Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice, RCT (PREDICT)
Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice (PREDICT), Randomized Control Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cancer screening and management guidelines are moving from a "one size fits all" approach to one that is tailored to an individual. Cervical Cancer Screening Management (CCSM) is the first example of a guideline that incorporates longitudinal screening history to personalize risk assessment. While a personalized approach offers the promise of enhancing the balance of benefits vs. harms of screening and management, this ideal can only be realized through strong systems to support care delivery. Without IT tools that integrate personalized algorithms with care delivery, more errors of judgement may occur if practitioners and patients are confused about appropriate next steps. The investigators hypothesize that delivering risk based CCSM to all eligible individuals will require: 1) using a generalizable Clinical Decision Support (CDS) tool that is validated and open source to implement the American Society for Colposcopy and Cervical Pathology (ASCCP) recommendations; 2) leveraging a system level health IT platform to present risk-based, personalized recommendations; and 3) offering a stepped care approach that individually engages patients and primary care physicians (PCP); and 4) enhances team-functioning, with increasing intensity over time (Figure 1). Accordingly, the investigators propose to develop, implement, and rigorously test PREDICT (Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice) within 4 primary care practice networks.
PREDICT components include supporting individual patient and practitioner engagement, and enhancing team coordination through an efficient "stepped care" approach. This will be compared to standard care by the patient's care team using a 3-arm, randomized design that will allow us to examine the marginal and cumulative effectiveness of the intervention components.
The study will be conducted in four primary care networks that are part of a large healthcare system (Mass General Brigham [MGB]): two affiliated with academic medical centers (Brigham and Women's Hospital [BWH] and Massachusetts General Hospital [MGH]), and two affiliated with community hospitals (Newton Wellesley Hospital [NWH] and North Shore Medical Center [NSMC])
PREDICT will include multilevel components. These will be tested using the 3-arm design that allows assessment of the sequential addition of these components. This design will also evaluate changing the responsibility for "opportunistic" follow-up, typically by the practitioner or patient at the time of a visit, to a systematic, multilevel approach, examining the cumulative and marginal effects of each subsequent level of intervention. In addition to the multilevel components, the individual- and team-level engagement algorithm will take a "stepped care" approach with increasing level of intensity of engagement
Step 1 will start 90 days before the date an individual is due for follow-up ("due date"), at the time of enrollment, based on the patient's personalized risk score. For example, Step 1 for a patient with a 5-year CIN 3+ risk of 0.6% in a practice randomized to an intervention arm would automatically have a 1-year surveillance follow-up reminder set in the EHR. In these intervention practices, practitioners could access this information when in the patient's EHR or when the patient views the reminder in their patient portal. For practices randomized to Arm 3, Step 2 would begin with a patient being sent a reminder letter 90 day prior the due date via the patient portal or mailed if no portal account (Outreach 1). If needed, four weeks later a phone call from the outreach coordinator reminds patients of the follow-up date if scheduled or helps establish follow-up (Outreach 2). The coordinator could also place an order for a referral and send a reminder to the practitioner to sign it if appropriate. The coordinator will review and document any "alternative care plans" discussed by the PCP and patient. A SQL study database will include functionality for coordinators to know when a patient should be contacted, how many contacts have been made, and the outcome of those efforts. Intervention components in Arm 3 will differ for individuals recommended for 3-year surveillance and for individuals 65 years and older who have prior abnormalities that would warrant additional surveillance or diagnostic management. In Arm 3, individuals recommended for 3-year surveillance will only receive Outreach 1 reminder letters (the study will have insufficient resources to make phone calls). Since individuals 65 years and older who have prior abnormalities that would warrant additional surveillance or diagnostic management are more likely to have other comorbid conditions that may affect recommended follow-up, study coordinators will message practitioners prior to performing patient outreach.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jennifer S Hass, MD
- Phone Number: 617-724-1832
- Email: Jennifer.Haas@mgh.harvard.edu
Study Contact Backup
- Name: Amy J Wint, MSc
- Email: awint@mgh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Brigham
-
Contact:
- Lipika Samal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria, Individuals who:
- have a cervix and are 21-70 years old
- receive care at a participating primary care practice (i.e. PCP team visit within past 3 years)
- have had a Pap and/ or HPV test within the past 3.5 years
- has a CCSM result that suggest a 5-year risk of developing CIN3+ that warrants surveillance at 1 or 3 years, diagnostic colposcopy, or treatment (i.e., above average risk).
Inclusion of those up to age 70 is intended to identify individuals whose prior history does not meet screening exit criteria, and warrants surveillance or diagnostic care even though women with adequate prior screening can stop at age 65
Exclusion Criteria Individuals who:
- were diagnosed with cervical cancer/ CIN3+ prior to the most recent screening Pap or HPV test
- have had their cervix removed
- are not English or Spanish-speaking.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Arm 1: Standard Care
Patients will receive the usual care provided by their PCP, practice, and/or specialist.
|
|
|
Active Comparator: Arm 2: Visit Based Reminder
Visit based reminders for physicians and patients that will be seen in Epic and Patient Gateway
|
To identify patients due for CCSM, simplify test ordering/referral, and track follow-up, PREDICT will include: 1) automated updating of a patient's problem list with the current cervical screening finding, 2) automated updating of cervical cancer health maintenance topics to the appropriate time interval and follow-up test/ procedure through the use of modifiers, 3) "SmartSets" to standardize ordering of procedures/ specialty referrals.
|
|
Active Comparator: Arm 3: Population Health Outreach
Visit based reminders for physicians and patients that will be seen in Epic and Patient Gateway.
Patients will received outreach from a population health coordinator.
Patients will be sent educational materials, a reminder letter, and if needed, additional help scheduling their follow up appointment.
|
To identify patients due for CCSM, simplify test ordering/referral, and track follow-up, PREDICT will include: 1) automated updating of a patient's problem list with the current cervical screening finding, 2) automated updating of cervical cancer health maintenance topics to the appropriate time interval and follow-up test/ procedure through the use of modifiers, 3) "SmartSets" to standardize ordering of procedures/ specialty referrals.
Patients will be sent a reminder letter 90 days prior to the due date via the patient portal or mailed if no portal account (Outreach 1).
If needed, four weeks later a phone call from the outreach coordinator reminds patients of the follow-up date if scheduled or helps establish follow-up (Outreach 2).
The coordinator could also place an order for a referral and send a reminder to the practitioner to sign it if appropriate.
The coordinator will review and document any "alternative care plans" discussed by the PCP and patient.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Primary effectiveness outcome
Time Frame: 120 days
|
The primary effectiveness outcome, measured at the patient level, is receipt of follow-up within 120 days of the due date, extracted from EHR/ associated claims documentation, for individuals with a 5-year risk of developing CIN3+ of 0.6% or more.
This time interval was selected to allow patients sufficient time to move through the stepped care intervention with enough time to schedule recommended follow-up given practitioner availability
|
120 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Secondary effectiveness outcome
Time Frame: 240 days
|
The secondary effectiveness outcome, number of days to completion over a 240 day follow-up period, to examine whether follow-up occurs as quickly as possible with censoring at the end of study period for patients who never receive follow-up.
|
240 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Uterine Diseases
- Genital Diseases, Female
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Neoplasms
- Uterine Cervical Neoplasms
Other Study ID Numbers
- 24-646
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.